Sugi Predict

Sugi Predict / Compounds / SCHEMBL17007232

SCHEMBL17007232

SCHEMBL17007232

O=C(O)c1ncccc1-n1cccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 1/20 0.55
▸ LMNA P02545 3/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ BLM P54132 1/20 0.49
▸ AGER Q15109 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ HCRTR1 O43613 5/20 0.45
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ G6PD P11413 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884579 0.85 IRAK4 (0.45) MYCLMNAKDM4EMAPTALDH1A1
SCHEMBL30761115 0.85 IRAK4 (0.45) MYCLMNAKDM4EMAPTALDH1A1
SCHEMBL21988904 0.85 HCRTR1 (0.44) MYCLMNAKDM4EMAPTALDH1A1
SCHEMBL28102316 0.79 HCRTR1 (0.41) MYCLMNAKDM4EMAPTALDH1A1
SCHEMBL17443084 0.78 KMT2A (0.52) ALDH1A1HCRTR1KMT2AGAACAPN1
SCHEMBL17714388 0.77 LMNA (0.49) MYCLMNAKDM4EMAPTALDH1A1
SCHEMBL608802 0.77 MYC (0.60) MYCLMNAKDM4EMAPTALDH1A1
SCHEMBL28300532 0.77 MAPK1 (0.50) LMNAKDM4EMAPTALDH1A1CYP3A4
SCHEMBL262384 0.76 HCRTR2 (0.45) LMNAKDM4EMAPTALDH1A1HCRTR1
SCHEMBL31175345 0.76 HCRTR2 (0.45) LMNAKDM4EMAPTALDH1A1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049326-A1 TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 BIOCRYST PHARMACEUTICALS, INC. (US) 2025-03-06 — — WO disclosed
US-12103921-B2 Chemical compounds PFIZER INC. (US) 2024-10-01 — — US disclosed
US-20230382892-A1 Chemical Compounds PFIZER INC. (US) 2023-11-30 — — US disclosed
US-11702405-B2 Chemical compounds PFIZER INC. (US) 2023-07-18 — — US disclosed
US-20220348555-A1 Chemical Compounds PFIZER INC. (US) 2022-11-03 — — US disclosed
EP-3107898-B1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICALS CO (JP) 2021-01-06 — — EP disclosed
US-10689373-B2 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-06-23 — — US disclosed
CN-106164047-B 1,2- substituted cyclopentane as orexin receptor antagonists 武田药品工业株式会社 2019-04-16 — — CN disclosed
US-20180282309-A1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-04 — — US disclosed
US-10011588-B2 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-07-03 — — US disclosed
US-20170066744-A1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 — — US disclosed
EP-3107898-A1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2016-12-28 — — EP disclosed
CN-106164047-A 1,2 substituted cyclopentanes as orexin receptor antagonists 武田药品工业株式会社 2016-11-23 — — CN disclosed
US-9156829-B2 Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-13 — — US disclosed
WO-2015124932-A1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS TAKEDA CAMBRIDGE LIMITED (GB) 2015-08-27 — — WO disclosed
US-20150232460-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282309-A1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, NPY1R MYC 3999/4885LMNA 1959/4885KDM4E 1117/4885
US-11702405-B2 Chemical compounds HBZ, HBB, HBS1L MYC 3886/4885LMNA 748/4885KDM4E 2745/4885
US-20230382892-A1 Chemical Compounds HBZ, HBB, HBS1L MYC 3886/4885LMNA 748/4885KDM4E 2745/4885
US-10011588-B2 1,2-substituted cyclopentanes as orexin receptor antagonists HCRTR1, HCRTR2, NPY1R MYC 3936/4885LMNA 2103/4885KDM4E 1154/4885
US-12103921-B2 Chemical compounds HBZ, HBB, HBS1L MYC 3886/4885LMNA 748/4885KDM4E 2745/4885
US-20220348555-A1 Chemical Compounds HBZ, HBB, HBS1L MYC 3886/4885LMNA 748/4885KDM4E 2745/4885
US-20170066744-A1 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, NPY1R MYC 3936/4885LMNA 2103/4885KDM4E 1154/4885
US-10689373-B2 1,2-substituted cyclopentanes as orexin receptor antagonists HCRTR1, HCRTR2, NPY1R MYC 3999/4885LMNA 1959/4885KDM4E 1117/4885
US-20150232460-A1 NOVEL COMPOUNDS CNKSR1, RDX, RB1 MYC 3928/4885LMNA 1103/4885KDM4E 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.